TCRT (Alaunos Therapeutics) Insider Ownership: 63.06 % (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCRT Alaunos Therapeutics Inc TCRT
29 GF Score
Price $1.98
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Insider Ownership?

Alaunos Therapeutics TCRT +1.54% 29 Insider Ownership is 63.06 % as of Aug. 11, 2026. GuruFocus rates TCRT with a GF Score™ of 29/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alaunos Therapeutics's insider ownership is 63.06%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alaunos Therapeutics's Institutional Ownership is 5.16%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alaunos Therapeutics's Float Percentage Of Total Shares Outstanding is 91.89%.

Alaunos Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Insider Ownership Chart

Alaunos Therapeutics Historical Data

The historical data trend for Alaunos Therapeutics can be seen below:

2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30
Insider Ownership 4.20 4.20 4.20 4.20 62.94 62.94 62.94 62.94 63.06 63.06
TCRT
29GF Score
Alaunos Therapeutics Inc TCRT
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 63.06 % mean?
Alaunos Therapeutics (TCRT) has a Insider Ownership of 63.06 % as of Aug. 11, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Alaunos Therapeutics and its competitors.
Is Alaunos Therapeutics' Insider Ownership too high?
Alaunos Therapeutics' current Insider Ownership is 63.06 %. Overall, Alaunos Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Insider Ownership compare to JAGX and LABT?
Alaunos Therapeutics' Insider Ownership of 63.06 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Insider Ownership is 63.06 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $1.98 — trading 191.2% above its estimated fair value. The current Insider Ownership is 63.06 %. Alaunos Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Insider Ownership is 63.06 % as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $1.98 is trading 191.2% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Insider Ownership: 63.06 %
  • GF Value™: $0.68 vs. price of $1.98 (191.2% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
29GF Score

Get the complete analysis for TCRT

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.98
Price
$0.68
GF Value